Multigenerational exposure to ethinyl estradiol affects bone geometry, but not bone mineral density in rats

Bone

Volumn 43, Issue 1, 2008, Pages 110-118

  Hotchkiss, Charlotte E ^a   Weis, Connie ^a   Blaydes, Betty ^a   Newbold, Retha ^b   Delclos, K Barry ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Bone development; Bone mineral density; Endocrine disruptors; Estrogen; Rat

Indexed keywords

ETHINYLESTRADIOL;

ABSORPTIOMETRY; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE DEVELOPMENT; BONE MINERAL; CORTICAL BONE; DIETARY INTAKE; FEMALE; FEMUR; GENETIC EPIGENESIS; MALE; MORPHOMETRICS; NEWBORN; NONHUMAN; RAT; WEIGHT CHANGE;

ABSORPTIOMETRY, PHOTON; ANIMALS; BONE AND BONES; BONE DENSITY; ETHINYL ESTRADIOL; RATS;

EID: 44949125363     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.03.016     Document Type: Article

References (89)

1. NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
2. Wasnich R.D. Epidemiology of osteoporosis. In: Favus M.J. (Ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fourth edition ed (1999), Lippincott Williams & Wilkins, Philadelphia, PA 257-259
3. Cheng X.G., Lowet G., Boonen S., Nicholson P.H., Van der Perre G., and Dequeker J. Prediction of vertebral and femoral strength in vitro by bone mineral density measured at different skeletal sites. J Bone Miner Res 13 (1998) 1439-1443
4. Ebbesen E.N., Thomsen J.S., Beck-Nielsen H., Nepper-Rasmussen H.J., and Mosekilde L. Lumbar vertebral body compressive strength evaluated by dual-energy X-ray absorptiometry, quantitative computed tomography, and ashing. Bone 25 (1999) 713-724
5. Turner C.H., Roeder R.K., Wieczorek A., Foroud T., Liu G., and Peacock M. Variability in skeletal mass, structure, and biomechanical properties among inbred strains of rats. J Bone Miner Res 16 (2001) 1532-1539
6. Compston J.E. Sex steroids and bone. Physiol Rev 81 (2001) 419-447 l
7. Stepan J.J., Alenfeld F., Boivin G., Feyen J.H., and Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 37 (2003) 225-238
8. Wanichsetakul P., Kamudhamas A., Watanaruangkovit P., Siripakarn Y., and Visutakul P. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 65 (2002) 407-410
9. Hreshchyshyn M.M., Hopkins A., Zylstra S., and Anbar M. Associations of parity, breast-feeding, and birth control pills with lumbar spine and femoral neck bone densities. Am J Obstet Gynecol 159 (1988) 318-322
10. Murphy S., Khaw K.T., and Compston J.E. Lack of relationship between hip and spine bone mineral density and oral contraceptive use. Eur J Clin Invest 23 (1993) 108-111
11. Mazess R.B., and Barden H.S. Bone density in premenopausal women: effects of age, dietary intake, physical activity, smoking, and birth-control pills. Am J Clin Nutr 53 (1991) 132-142
12. Endrikat J., Mih E., Dusterberg B., Land K., Gerlinger C., Schmidt W., et al. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 mg or 30 mg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception 69 (2004) 179-187
13. Pasco J.A., Kotowicz M.A., Henry M.J., Panahi S., Seeman E., and Nicholson G.C. Oral contraceptives and bone mineral density: a population-based study. Am J Obstet Gynecol 182 (2000) 265-269
14. Enzelsberger H., Metka M., Heytmanek G., Schurz B., Kurz C., and Kusztrich M. Influence of oral contraceptive use on bone density in climacteric women. Maturitas 9 (1988) 375-378
15. Stevenson J.C., Lees B., Devenport M., Cust M.P., and Ganger K.F. Determinants of bone density in normal women: risk factors for future osteoporosis?. BMJ 298 (1989) 924-928
16. Kleerekoper M., Brienza R.S., Schultz L.R., and Johnson C.C. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group. Arch Intern Med 151 (1991) 1971-1976
17. Kritz-Silverstein D., and Barrett-Connor E. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use. Am J Public Health 83 (1993) 100-102
18. Lindsay R., Tohme J., and Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women. Contraception 34 (1986) 333-340
19. Prior J.C., Kirkland S.A., Joseph L., Kreiger N., Murray T.M., Hanley D.A., et al. Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study. CMAJ 165 (2001) 1023-1029
20. Michaelsson K., Baron J.A., Farahmand B.Y., Persson I., and Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 353 (1999) 1481-1484
21. Cooper C., Hannaford P., Croft P., and Kay C.R. Oral contraceptive pill use and fractures in women: a prospective study. Bone 14 (1993) 41-45
22. Vessey M., Mant J., and Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception 57 (1998) 231-235
23. Nappi C., Di Spiezio Sardo A., Greco E., Tommaselli G.A., Giordano E., and Guida M. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density. Obstet Gynecol 105 (2005) 53-60
24. Reed S.D., Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception 68 (2003) 177-182
25. Berenson A.B., Breitkopf C.R., Grady J.J., Rickert V.I., and Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 103 (2004) 899-906
26. Paoletti A.M., Orru M., Lello S., Floris S., Ranuzzi F., Etzi R., et al. Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 mg of ethinyl estradiol: observational study in young postadolescent women. Contraception 70 (2004) 293-298
27. Rome E., Ziegler J., Secic M., Bonny A., Stager M., Lazebnik R., et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J Pediatr Adolesc Gynecol 17 (2004) 373-377
28. Lloyd T., Taylor D.S., Lin H.M., Matthews A.E., Eggli D.F., and Legro R.S. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. Fertil Steril 74 (2000) 734-738
29. Recker R.R., Davies K.M., Hinders S.M., Heaney R.P., Stegman M.R., and Kimmel D.B. Bone gain in young adult women. JAMA 268 (1992) 2403-2408
30. Cobb K.L., Kelsey J.L., Sidney S., Ettinger B., and Lewis C.E. Oral contraceptives and bone mineral density in white and black women in CARDIA. Osteoporos Int 13 (2002) 893-900
31. Burr D.B., Yoshikawa T., Teegarden D., Lyle R., McCabe G., McCabe L.D., et al. Exercise and oral contraceptive use suppress the normal age-related increase in bone mass and strength of the femoral neck in women 18-31 years of age. Bone 27 (2000) 855-863
32. Mais V., Fruzzetti F., Ajossa S., Paoletti A.M., Guerriero S., and Melis G.B. Bone metabolism in young women taking a monophasic pill containing 20 mcg ethinylestradiol: a prospective study. Contraception 48 (1993) 445-452
33. Polatti F., Perotti F., Filippa N., Gallina D., and Nappi R.E. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 51 (1995) 221-224
34. Cromer B.A. Bone mineral density in adolescent and young adult women on injectable or oral contraception. Curr Opin Obstet Gynecol 15 (2003) 353-357
35. Hartard M., Bottermann P., Bartenstein P., Jeschke D., and Schwaiger M. Effects on bone mineral density of low-dosed oral contraceptives compared to and combined with physical activity. Contraception 55 (1997) 87-90
36. Weaver C.M., Teegarden D., Lyle R.M., McCabe G.P., McCabe L.D., Proulx W., et al. Impact of exercise on bone health and contraindication of oral contraceptive use in young women. Med Sci Sports Exerc 33 (2001) 873-880
37. Cromer B.A., Stager M., Bonny A., Lazebnik R., Rome E., Ziegler J., et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 35 (2004) 434-441
38. Wang L., McMahan C.A., Banu J., Okafor M.C., and Kalu D.N. Rodent model for investigating the effects of estrogen on bone and muscle relationship during growth. Calcif Tissue Int 72 (2003) 151-155
39. Dubuc P.U. Prepuberal estrogen treatment and somatic growth in rats. Endocrinology 98 (1976) 623-629
40. Gustafsson P.O., Kasstrom H., Lindberg L., and Olsson S.E. Growth and mitotic rate of the proximal tibial epiphyseal plate in hypophysectomized rats given estradiol and human growth hormone. Acta Radiol Suppl 344 (1975) 69-74
41. Jansson J.O., Eden S., and Isaksson O. Sites of action of testosterone and estradiol on longitudinal bone growth. Am J Physiol 244 (1983) E135-E140
42. Chow J.W., Lean J.M., and Chambers T.J. 17 beta-estradiol stimulates cancellous bone formation in female rats. Endocrinology 130 (1992) 3025-3032
43. Cikos S., Kuchar S., and Koppel J. The effect of administration of estradiol and testosterone on body growth of young male rats. Physiol Res 41 (1992) 387-392
44. Cikos S., Kuchar S., and Koppel J. The longitudinal growth of tibia in oestradiol-treated and restrictedly fed immature male rats. Physiol Res 43 (1994) 141-143
45. Aceitero J., Gaytan F., and Ranz F.B. Effects of neonatal estrogenization on rat bone development: a histomorphometric study. Calcif Tissue Int 40 (1987) 189-193
46. Westerlind K.C., Wakley G.K., Evans G.L., and Turner R.T. Estrogen does not increase bone formation in growing rats. Endocrinology 133 (1993) 2924-2934
47. Whitson S.W., Dawson L.R., and Jee W.S. A tetracycline study of cyclic longitudinal bone growth in the female rat. Endocrinology 103 (1978) 2006-2010
48. Wronski T.J., Cintron M., Doherty A.L., and Dann L.M. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 123 (1988) 681-686
49. Wronski T.J., Dann L.M., Scott K.S., and Crooke L.R. Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats. Endocrinology 125 (1989) 810-816
50. Turner R.T., Vandersteenhoven J.J., and Bell N.H. The effects of ovariectomy and 17 beta-estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res 2 (1987) 115-122
51. Turner R.T., Evans G.L., Sluka J.P., Adrian M.D., Bryant H.U., Turner C.H., et al. Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene. Endocrinology 139 (1998) 3712-3720
52. Chen H.K., Ke H.Z., Lin C.H., Ma Y.F., Qi H., Crawford D.T., et al. Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats. Bone 17 (1995) 175S-179S
53. Ke H.Z., Chen H.K., Simmons H.A., Qi H., Crawford D.T., Pirie C.M., et al. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 20 (1997) 31-39
54. Ke H.Z., Paralkar V.M., Grasser W.A., Crawford D.T., Qi H., Simmons H.A., et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 139 (1998) 2068-2076
55. Eleftheriades M.I., Lambrinoudaki I.V., Christodoulakos G.E., Gregoriou O.V., Economou E.V., Kouskouni E.E., et al. Effect of oral contraceptive treatment on bone mass acquisition in skeletally immature young female rats. Contraception 71 (2005) 362-371
56. Turner R.T., Hannon K.S., Demers L.M., Buchanan J., and Bell N.H. Differential effects of gonadal function on bone histomorphometry in male and female rats. J Bone Miner Res 4 (1989) 557-563
57. Turner R.T., Wakley G.K., and Hannon K.S. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 8 (1990) 612-617
58. Twaddle N.C., Churchwell M.I., Newbold R.R., Delclos K.B., and Doerge D.R. Determination using liquid-chromatography-electrospray tandem mass spectroscopy of ethinylestradiol serum pharmacokinetics in adult Sprague-Dawley rats. J Chromatogr B Analyt Technol Biomed Life Sci 793 (2003) 309-315
59. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2 (1987) 595-610
60. Eastell R. Role of oestrogen in the regulation of bone turnover at the menarche. J Endocrinol 185 (2005) 223-234
61. Kapitola J., Schreiber V., Andrle J., and Kubickova J. Different effects of oestradiol benzoate and norethisterone on the blood flow and mineral content in rat bones. Physiol Res 41 (1992) 393-398
62. Turner R.T., Evans G.L., and Wakley G.K. Reduced chondroclast differentiation results in increased cancellous bone volume in estrogen-treated growing rats. Endocrinology 134 (1994) 461-466
63. Bemben D.A., Boileau R.A., Bahr J.M., Nelson R.A., and Misner J.E. Effects of oral contraceptives on hormonal and metabolic responses during exercise. Med Sci Sports Exerc 24 (1992) 434-441
64. Garnero P., Sornay-Rendu E., and Delmas P.D. Decreased bone turnover in oral contraceptive users. Bone 16 (1995) 499-503
65. Parfitt A.M. Misconceptions (1): epiphyseal fusion causes cessation of growth. Bone 30 (2002) 337-339
66. Husain S.M., Brazeau Jr. P., and Saucier R. Inhibition of growth and width of tibial cartilage in rats by a contraceptive agent. Growth 33 (1969) 17-24
67. Kardinaal A.F., Hoorneman G., Vaananen K., Charles P., Ando S., Maggiolini M., et al. Determinants of bone mass and bone geometry in adolescent and young adult women. Calcif Tissue Int 66 (2000) 81-89
68. Soon G., Quintin A., Scalfo F., Antille N., Williamson G., Offord E., et al. PIXImus bone densitometer and associated technical measurement issues of skeletal growth in the young rat. Calcif Tissue Int 78 (2006) 186-192 l
69. Trovas G., Lyritis G.P., Galanos A., Raptou P., and Katsiri M. Influence of weight gain on spine mineral density in postmenopausal women. Calcif Tissue Int 64 (1999) 380-383
70. Valdimarsson O., Kristinsson J.O., Stefansson S.O., Valdimarsson S., and Sigurdsson G. Lean mass and physical activity as predictors of bone mineral density in 16-20-year old women. J Intern Med 245 (1999) 489-496
71. Carani C., Qin K., Simoni M., Faustini-Fustini M., Serpente S., Boyd J., et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337 (1997) 91-95
72. Morishima A., Grumbach M.M., Simpson E.R., Fisher C., and Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80 (1995) 3689-3698
73. Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331 (1994) 1056-1061
74. Duan Y., Turner C.H., Kim B.T., and Seeman E. Sexual dimorphism in vertebral fragility is more the result of gender differences in age-related bone gain than bone loss. J Bone Miner Res 16 (2001) 2267-2275
75. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 359 (2002) 1841-1850
76. Orwoll E.S., and Klein R.F. Osteoporosis in men. Endocr Rev 16 (1995) 87-116 l
77. Broulik P.D., Rosenkrancova J., Ruzicka P., and Sedlacek R. Effects of triiodothyronine and estrogen administration on bone mass, mineral content and bone strength in male rats. Horm Metab Res 35 (2003) 527-531
78. Ross J.L., Cassorla F.G., Skerda M.C., Valk I.M., Loriaux D.L., and Cutler Jr. G.B. A preliminary study of the effect of estrogen dose on growth in Turner's syndrome. N Engl J Med 309 (1983) 1104-1106
79. Anderson J.J., Ambrose W.W., and Garner S.C. Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model. Proc Soc Exp Biol Med 217 (1998) 345-350
80. Hotchkiss C.E., Weis C., Blaydes B., Newbold R., and Delclos K.B. Multigenerational exposure to genistein does not increase bone mineral density in rats. Bone 37 (2005) 720-727
81. National Toxicology Program. NTP technical report on the multigenerational reproductive toxicology study of ethinyl estradiol (CAS No. 57-63-6) in Sprague-Dawley rats (feed studies). Natl Toxicol Program Tech Rep Ser 547: in press.
82. Gertner J.M. Childhood and adolescence. In: Favus M.J. (Ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fourth edition ed. (1999), Lippincott Williams & Wilkins, Philadelphia, PA 45-59
83. National Toxicology Program. NTP technical report on the toxicology and carcinogenesis study of ethinyl estradiol (CAS No. 57-63-6) in Sprague-Dawley rats (feed studies). Natl Toxicol Program Tech Rep Ser 548: in press.
84. Waterland R.A., and Jirtle R.L. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 20 (2004) 63-68
85. Gallou-Kabani C., and Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes 54 (2005) 1899-1906
86. Gluckman P.D., and Hanson M.A. Living with the past: evolution, development, and patterns of disease. Science 305 (2004) 1733-1736
87. Anway M.D., Cupp A.S., Uzumcu M., and Skinner M.K. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 308 (2005) 1466-1469
88. Anway M.D., and Skinner M.K. Epigenetic transgenerational actions of endocrine disruptors. Endocrinology 147 (2006) s43-s49
89. Wuttke W., Jarry H., Westphalen S., Christoffel V., and Seidlova-Wuttke D. Phytoestrogens for hormone replacement therapy?. J Steroid Biochem Mol Biol 83 (2003) 133-147